Latest news with #TrivariateResearch
CNBC
2 days ago
- Business
- CNBC
CNBC Daily Open: Tariff letters from Trump, like those of lovers, seem to signify little
Paramours wanting to court each other have, through the decades, moved on from love letters to Instagram DMs. But some form of that epistolary tradition remains today in the stately realm of politics. U.S. President Donald Trump revealed Monday that he had written letters to the leaders of 12 countries, informing them of new tariff rates due to begin on Aug. 1. Upon first reading, the letter is enough to send the heart racing. It contains bold emotional declarations ("You will never be disappointed with The United States of America"), big double-digit numbers (between 25% and 40%, depending on the recipient) and a veiled threat should desire not be reciprocated ("These tariffs may be modified … depending on our relationship with your Country"). But if we take a step back, it appears that he letters' purpose might not be that different from the table of "reciprocal" tariffs Trump hoisted up at the White House's Rose Garden in April. The letters threaten stiff tariffs that will kick in on a certain date (or as certain as any deadline from the White House can be), unless countries negotiate with the U.S. for a trade deal. Even the tariff numbers aren't that far from what was initially revealed. In other words, the letters might just be a restaging of April's events. "If you go through the details, I don't even know if anybody understands the difference between what was announced today, what was there previously, and if it will actually be implemented, and which companies it actually impacts," Trivariate Research CEO Adam Parker said Monday on CNBC's "Closing Bell." Trump on Sunday, in response to whether the deadline for tariffs will be changing, said, "They're going to be tariffs. The tariffs are going to be the tariffs." In the same way, a tariff is a tariff is a tariff, whether in a racy letter, stated on a big chart, or even sent in an Instagram DM. Steep tariffs on 14 countries. The White House on Monday sent letters to leaders of several countries announcing blanket tariffs ranging from 25% to 40% starting Aug. 1. Japan's Prime Minister Shigeru Ishiba on Tuesday called Trump's latest tariffs "regrettable." U.S. markets fall on stiff tariffs. All major U.S. indexes ended in the red on Monday, their worst session in almost a month. Asia-Pacific markets mostly rose Tuesday, but Australia's S&P/ASX 200 fell after the country's central bank unexpectedly held interest rates. Tesla loses more than $68 billion in value. Shares of the electric vehicle maker tumbled 6.8% after Tesla CEO Elon Musk said Saturday he was forming a new U.S. political party. Investors are worried about Musk heading deeper into politics. Samsung Electronics forecasts a 56% fall in profits. Second-quarter operating profit is expected to come in around 4.6 trillion Korean won ($3.3 billion), a steep decline from 10.44 trillion won a year ago. The firm's estimate is even lower than analyst expectations. [PRO] Safe spots in the Chinese market. While the China technology story hasn't changed enough to warrant major changes to portfolios, analysts are encouraging investors to be more conservative as they gear up for the second half. Tariffs, declining real wages, slowing growth: Japan's central bank has its work cut out The Bank of Japan faces a stiff challenge: normalizing its monetary policy as growth slows amid steep U.S. tariffs, while real wages decline because of inflation. Real wages dropped at their fastest pace in 20 months in May, pressuring the central bank to raise rates and rein in inflation. But an economic slowdown appears to be constraining the bank's ability to tighten policy.
CNBC
2 days ago
- Business
- CNBC
CNBC Daily Open: Trump's tariff letters set the heart racing, but don't seem to promise anything new
Paramours wanting to court each other have, through the decades, moved on from courtly love letters to raunchy Instagram DMs. But some form of that epistolary tradition remains today in the stately realm of politics. U.S. President Donald Trump revealed Monday that he had written letters to the leaders of 12 countries, informing them of new tariff rates due to begin on Aug. 1. Upon first reading, the letter is enough to send the heart racing. It contains bold emotional declarations ("You will never be disappointed with The United States of America"), big double-digit numbers (between 25% and 40%, depending on the recipient) and a veiled threat should desire not be reciprocated ("These tariffs may be modified … depending on our relationship with your Country"). But if we take a step back, it appears that he letters' purpose might not be that different from the table of "reciprocal" tariffs Trump hoisted up at the White House's Rose Garden in April. The letters threaten stiff tariffs that will kick in on a certain date (or as certain as any deadline from the White House can be), unless countries negotiate with the U.S. for a trade deal. Even the tariff numbers aren't that far from what was initially revealed. In other words, the letters might just be a restaging of April's events. "If you go through the details, I don't even know if anybody understands the difference between what was announced today, what was there previously, and if it will actually be implemented, and which companies it actually impacts," Trivariate Research CEO Adam Parker said Monday on CNBC's "Closing Bell." Trump on Sunday, in response to whether the deadline for tariffs will be changing, said, "They're going to be tariffs. The tariffs are going to be the tariffs." In the same way, a tariff is a tariff is a tariff, whether in a racy letter, stated on a big chart, or even sent in an Instagram DM. Steep tariffs on 14 countries. The White House sent letters to leaders of several countries announcing blanket tariffs ranging from 25% to 40% starting Aug. 1. Notably, U.S. imports from Japan and South Korea face a 25% duty. U.S. markets fall on stiff tariffs. All major U.S. indexes ended in the red in their worst day in almost a month. The Stoxx Europe 600 rose 0.44%. Oil and gas stocks fell after the OPEC+ alliance on Saturday agreed to a bigger-than-expected production increase. Tesla loses more than $68 billion in value. Shares of the electric vehicle maker tumbled 6.8% after Tesla CEO Elon Musk said Saturday he was forming a new U.S. political party. Investors are worried about Musk heading deeper into politics. Samsung Electronics forecasts a 56% fall in profits. Second-quarter operating profit is expected to come in around 4.6 trillion Korean won ($3.3 billion), a steep decline from 10.44 trillion won a year ago. The firm's estimate is even lower than analyst expectations. [PRO] Safe spots in the Chinese market. While the China technology story hasn't changed enough to warrant major changes to portfolios, analysts are encouraging investors to be more conservative as they gear up for the second half. This Chinese jeweler is using traditional techniques to challenge Cartier — and it's starting in Singapore Laopu Gold opened its first overseas store in Singapore on June 21, just outside the Marina Bay Sands casino. During the first two weekends, wait times stretched from one to two hours, according to an employee. The Chinese jeweler has excited investors with its surging China sales — up 166% to 9.8 billion yuan ($1.37 billion) in 2024, according to its annual report. The company's shares have skyrocketed by well over 2,000% since its public offering price of HK$40.50 in Hong Kong in June 2024.
CNBC
30-06-2025
- Business
- CNBC
Trivariate's Adam Parker: Investors aren't worried about dollar weakening
Adam Parker, Trivariate Research founder and CEO, joins CNBC's 'Squawk on the Street' to discuss weakness in the dollar, what sectors he's looking at for the second half of the year, and more.
Yahoo
19-06-2025
- Business
- Yahoo
Adam Parker of Trivariate Research Recommends Eli Lilly's Dividend as a Defensive Play
Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at select dividend-paying stocks. In a note dated June 8, Parker mentioned that while many institutional investors still expect the S&P to climb higher, there's also growing interest in identifying solid defensive options. An array of pharmaceutical pills with the company's logo on the bottle. He noted that the 'old school' strategy of leaning on traditional defensive sectors like consumer staples, pharmaceuticals, and telecoms appears to be 'broken.' In response, Trivariate has outlined alternative strategies for defensive positioning, one of which includes focusing on dividend-paying equities. Parker made the following comment: 'We think companies with consistent dividend growth are likely to provide strong defense if there's a growth scare. Specifically, our past work shows that companies that have grown their dividend over the last five years and that are indicated to have continued dividend growth, as well as at least 7% forecasted sales growth and 10% forecasted earnings growth outperform.' Eli Lilly and Company (NYSE:LLY) was the only pharmaceutical company to make the list. The firm offers a dividend yield of 0.76% and has seen its stock has surged by nearly 2% year-to-date. In May, the company posted better-than-expected earnings and revenue for the first quarter but trimmed its full-year profit outlook due to costs tied to a cancer drug deal. However, it kept its full-year sales forecast unchanged. Following the earnings release, CEO Dave Ricks told CNBC that the potential market for its widely used weight-loss and diabetes medications is 'massive.' Eli Lilly and Company (NYSE:LLY)'s diabetes drug is Mounjaro, while Zepbound is its treatment for obesity. Ricks made the following statement in an interview with ' Squawk Box ' on May 1: 'Today we probably have about 10 million Americans taking GLP-1s. The market opportunity is much, much larger than that. We see this as a big wave of innovation for many years to come and Lilly is at the forefront of that.' According to FactSet, Eli Lilly and Company (NYSE:LLY) holds an average rating of 'Overweight,' with analysts projecting nearly 21% upside based on the stock's average price target. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
18-06-2025
- Business
- Yahoo
Adam Parker of Trivariate Research Recommends Eli Lilly's Dividend as a Defensive Play
Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at select dividend-paying stocks. In a note dated June 8, Parker mentioned that while many institutional investors still expect the S&P to climb higher, there's also growing interest in identifying solid defensive options. An array of pharmaceutical pills with the company's logo on the bottle. He noted that the 'old school' strategy of leaning on traditional defensive sectors like consumer staples, pharmaceuticals, and telecoms appears to be 'broken.' In response, Trivariate has outlined alternative strategies for defensive positioning, one of which includes focusing on dividend-paying equities. Parker made the following comment: 'We think companies with consistent dividend growth are likely to provide strong defense if there's a growth scare. Specifically, our past work shows that companies that have grown their dividend over the last five years and that are indicated to have continued dividend growth, as well as at least 7% forecasted sales growth and 10% forecasted earnings growth outperform.' Eli Lilly and Company (NYSE:LLY) was the only pharmaceutical company to make the list. The firm offers a dividend yield of 0.76% and has seen its stock has surged by nearly 2% year-to-date. In May, the company posted better-than-expected earnings and revenue for the first quarter but trimmed its full-year profit outlook due to costs tied to a cancer drug deal. However, it kept its full-year sales forecast unchanged. Following the earnings release, CEO Dave Ricks told CNBC that the potential market for its widely used weight-loss and diabetes medications is 'massive.' Eli Lilly and Company (NYSE:LLY)'s diabetes drug is Mounjaro, while Zepbound is its treatment for obesity. Ricks made the following statement in an interview with ' Squawk Box ' on May 1: 'Today we probably have about 10 million Americans taking GLP-1s. The market opportunity is much, much larger than that. We see this as a big wave of innovation for many years to come and Lilly is at the forefront of that.' According to FactSet, Eli Lilly and Company (NYSE:LLY) holds an average rating of 'Overweight,' with analysts projecting nearly 21% upside based on the stock's average price target. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
